Innate Pharma Reports Q2 2026 Financial Results and Strategic Updates
Innate Pharma (IPHA) reported its second-quarter financial results for 2026, highlighting a net loss of €19.6 million in the first half compared to €21.3 million during the same period in 2025. The company secured significant capital through an upfront payment from Sobi and a recent equity offering, extending its cash runway until early 2028. Management emphasized strategic progress on key oncology programs, including lacutamab licensing and advancements in ADC technology. The firm's revenue for the first half of 2026 totaled €5.7 million, driven by collaboration agreements and research tax credits. Operating expenses decreased to €24.7 million from €30.3 million a year earlier due to cost reductions following restructuring efforts. The company is focused on three near-term catalysts: Phase 3 results for monalizumab in lung cancer, initial data for its Nectin-4 ADC program, and potential accelerated regulatory approvals. In addition, Innate Pharma outlined substantial milestone payments from partnerships with Sobi ($505 million) and AstraZeneca (up to $825 million), which could significantly impact future revenue. The company also provided pricing estimates for lacutamab in the U.S., ranging between €476,000 and €619,000 per patient annually.
Tickers: $AZN